silvercatpharma | from gold to silver: streamlining metal-catalysed cross-coupling reactions

Summary
Silvercatpharma project aims at developing C-C cross-coupling reactions catalysed by d11-blocks metals, particularly silver, for the synthesis of pharmaceuticals in Novartis. It strives to have an impact in terms of cost, environment and international visibility because of the use of silver as an alternative catalyst. The project offers me a great opportunity to obtain further training, such as clusters preparation, computational and flow chemistry, and to define my final career in academia or industry because of the possibility of working in these two different environments.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/658256
Start date: 01-04-2015
End date: 31-03-2017
Total budget - Public funding: 158 121,60 Euro - 158 121,00 Euro
Cordis data

Original description

Silvercatpharma project aims at developing C-C cross-coupling reactions catalysed by d11-blocks metals, particularly silver, for the synthesis of pharmaceuticals in Novartis. It strives to have an impact in terms of cost, environment and international visibility because of the use of silver as an alternative catalyst. The project offers me a great opportunity to obtain further training, such as clusters preparation, computational and flow chemistry, and to define my final career in academia or industry because of the possibility of working in these two different environments.

Status

CLOSED

Call topic

MSCA-IF-2014-EF

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2014
MSCA-IF-2014-EF Marie Skłodowska-Curie Individual Fellowships (IF-EF)